TAK-861
- Generic Name
- TAK-861
A Study of TAK-861 in People With Narcolepsy Type 1
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 105
- Registration Number
- NCT06505031
- Locations
- ๐ฆ๐น
Takeda Site 22, Linz, Austria
๐ง๐ชTakeda Site 25, Ghent, Belgium
๐ง๐ชTakeda Site 24, Leuven, Belgium
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 168
- Registration Number
- NCT06470828
- Locations
- ๐บ๐ธ
Takeda Site 1, Columbia, South Carolina, United States
๐บ๐ธTakeda Site 42, Cleveland, Ohio, United States
๐บ๐ธTakeda Site 49, Danville, Pennsylvania, United States
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 500
- Registration Number
- NCT05816382
- Locations
- ๐ฉ๐ช
Somni Bene Institut fur Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Mecklenburg-Vorpommern, Germany
๐ฎ๐นFondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy
๐ณ๐ดUniversity of Oslo, Oslo, Norway
A Study of TAK-861 in Participants With Narcolepsy Type 1
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 112
- Registration Number
- NCT05687903
- Locations
- ๐ฆ๐บ
Woolcock Institute of Medical Research, Sleep and Circadian Research Group, Glebe, New South Wales, Australia
๐ฏ๐ตKurume University Hospital, Kurume-Shi, Hukuoka, Japan
๐ฏ๐ตKoishikawa Tokyo Hospital, Bunkyo-Ku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.